Filter By Category
Archives
Share on -
AVALOTCAGENE ONTAPARVOVEC
Generic Name: AVALOTCAGENE ONTAPARVOVEC
ABSTRACT -
Avalotcagene ontaparvovec is an investigational AAV8-based gene therapy vector designed to deliver a functional ornithine transcarbamylase gene to liver cells for OTC deficiency. It is a viral-vector biologic and does not have a single small-molecule skeletal structure. The representation above is an AAV vector schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine clinical use unless specifically authorized in a local label.
- Clinical-study dosing, when applicable, is protocol-specific and must not be copied into routine practice.
- Do not administer outside an authorized clinical trial, compassionate-use pathway, or approved product labeling.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-related reactions, fever, chills, fatigue, or headache
- Transient liver enzyme elevation or immune response to the vector
- Nausea, abdominal discomfort, or flu-like symptoms
- Changes in ammonia management may require close metabolic monitoring
- Serious immune-mediated or hepatic adverse events are possible
ALLERGIC REACTIONS -
Hypersensitivity to Avalotcagene Ontaparvovec or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avalotcagene Ontaparvovec should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avalotcagene Ontaparvovec may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Immunosuppressive medicines may be required or adjusted by protocol.
- Live vaccines and other gene/cell therapies require specialist coordination.
- Hepatotoxic medicines may increase liver-risk monitoring needs.
- Patients should inform providers about all medicines, supplements, and vaccines.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use only in specialized centers with metabolic and gene-therapy expertise.
- Assess pre-existing AAV antibodies, liver function, and ammonia-control plan.
- Long-term follow-up is required after gene therapy exposure.
- Pregnancy and germline-risk considerations require protocol-specific counseling.
WARNINGS –
- Investigational status: safety and effectiveness for routine use may not be established.
- Serious or unexpected adverse events must be managed under protocol and reported promptly.
- Use only by personnel trained for the relevant formulation and administration route.
- Keep out of reach of children.
Share on -
. Developed by